Page 1569 - Williams Hematology ( PDFDrive )

1544 Part XI: Malignant Lymphoid Diseases Chapter 92: Chronic Lymphocytic Leukemia 1545

27. Ranheim EA, Cantwell MJ, Kipps TJ: Expression of CD27 and its ligand, CD70, on 57. Laurenti L, Piccioni P, Cattani P, et al: Cytomegalovirus reactivation during alemtu-
chronic lymphocytic leukemia B cells. Blood 85:3556–3565, 1995. zumab therapy for chronic lymphocytic leukemia: Incidence and treatment with oral
28. Klein U, Dalla-Favera R: New insights into the phenotype and cell derivation of B cell ganciclovir. Haematologica 89:1248–1252, 2004.
chronic lymphocytic leukemia. Curr Top Microbiol Immunol 294:31–49, 2005. 58. Hersey P, Wotherspoon J, Reid G, et al: Hypogammaglobulinaemia associated with
29. Klein U, Tu Y, Stolovitzky GA, et al: Gene expression profiling of B cell chronic lympho- abnormalities of both B and T lymphocytes in patients with chronic lymphatic leu-
cytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med kaemia. Clin Exp Immunol 39:698–707, 1980.
194:1625–1638, 2001. 59. Lacombe C, Gombert J, Dreyfus B, et al: Heterogeneity of serum IgG subclass deficien-
30. Geisler CH, Larsen JK, Hansen NE, et al: Prognostic importance of flow cytometric cies in B chronic lymphocytic leukemia. Clin Immunol 90:128–132, 1999.
immunophenotyping of 540 consecutive patients with B-cell chronic lymphocytic leu- 60. Sampalo A, Navas G, Medina F, et al: Chronic lymphocytic leukemia B cells inhibit
kemia. Blood 78:1795–1802, 1991. spontaneous Ig production by autologous bone marrow cells: Role of CD95-CD95L
31. Vilpo J, Tobin G, Hulkkonen J, et al: Surface antigen expression and correlation with interaction. Blood 96:3168–3174, 2000.
variable heavy-chain gene mutation status in chronic lymphocytic leukemia. Eur J 61. Herman SE, Mustafa RZ, Gyamfi JA, et al: Ibrutinib inhibits BCR and NF-kappaB sig-
Haematol 70:53–59, 2003. naling and reduces tumor proliferation in tissue-resident cells of patients with CLL.
32. Caligaris-Cappio F: B-chronic lymphocytic leukemia: A malignancy of anti-self B cells. Blood 123:3286–3295, 2014.
Blood 87:2615–2620, 1996. 62. Duhren-von Minden M, Ubelhart R, Schneider D, et al: Chronic lymphocytic leu-
33. Wardemann H, Yurasov S, Schaefer A, et al: Predominant autoantibody production by kaemia is driven by antigen-independent cell-autonomous signalling. Nature 489:
early human B cell precursors. Science 301:1374–1377, 2003. 309–312, 2012.
34. Awan FT, Kay NE, Davis ME, et al: Mcl-1 expression predicts progression-free survival 63. Pierce SK, Liu W: The tipping points in the initiation of B cell signalling: How small
in chronic lymphocytic leukemia patients treated with pentostatin, cyclophosphamide, changes make big differences. Nat Rev Immunol 10:767–777, 2010.
and rituximab. Blood 113:535–537, 2009. 64. Stevenson FK, Krysov S, Davies AJ, et al: B-cell receptor signaling in chronic lympho-
35. Petlickovski A, Laurenti L, Li X, et al: Sustained signaling through the B-cell receptor cytic leukemia. Blood 118:4313–4320, 2011.
induces Mcl-1 and promotes survival of chronic lymphocytic leukemia B cells. Blood 65. Chiorazzi N, Efremov DG: Chronic lymphocytic leukemia: A tale of one or two signals?
105:4820–4827, 2005. Cell Res 23:182–185, 2013.
36. Liu Z, Hazan-Halevy I, Harris DM, et al: STAT-3 activates NF-kappaB in chronic lym- 66. Buckley RH: Primary immunodeficiency diseases due to defects in lymphocytes. N Engl
phocytic leukemia cells. Mol Cancer Res 9:507–515, 2011. J Med 343:1313–1324, 2000.
37. Burger JA, Tsukada N, Burger M, et al: Blood-derived nurse-like cells protect chronic 67. Herman SE, Gordon AL, Hertlein E, et al: Bruton tyrosine kinase represents a promis-
lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived ing therapeutic target for treatment of chronic lymphocytic leukemia and is effectively
factor-1. Blood 96:2655–2663, 2000. targeted by PCI-32765. Blood 117:6287–6296, 2011.
38. Burger JA, Burger M, Kipps TJ: Chronic lymphocytic leukemia B cells express func- 68. Dubovsky JA, Beckwith KA, Natarajan G, et al: Ibrutinib is an irreversible molecular
tional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood 122:2539–
marrow stromal cells. Blood 94:3658–3667, 1999. 2549, 2013.
39. Herishanu Y, Perez-Galan P, Liu D, et al: The lymph node microenvironment promotes 69. Pogue SL, Kurosaki T, Bolen J, et al: B cell antigen receptor-induced activation of Akt
B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic promotes B cell survival and is dependent on Syk kinase. J Immunol 165:1300–1306,
lymphocytic leukemia. Blood 117:563–574, 2011. 2000.
40. Herishanu Y, Katz BZ, Lipsky A, et al: Biology of chronic lymphocytic leukemia in dif- 70. Srinivasan L, Sasaki Y, Calado DP, et al: PI3 kinase signals BCR-dependent mature B
ferent microenvironments: Clinical and therapeutic implications. Hematol Oncol Clin cell survival. Cell 139:573–586, 2009.
North Am 27:173–206, 2013. 71. Brown JR, Byrd JC, Coutre SE, et al: Idelalisib, an inhibitor of phosphatidylinositol
41. Zimmerman TS, Godwin HA, Perry S: Studies of leukocyte kinetics in chronic lympho- 3-kinase p110delta, for relapsed/refractory chronic lymphocytic leukemia. Blood
cytic leukemia. Blood 31:277–291, 1968. 123:3390–3397, 2014.
42. Andreeff M, Darzynkiewicz Z, Sharpless TK, et al: Discrimination of human leuke- 72. Awan FT, Byrd JC: New strategies in chronic lymphocytic leukemia: Shifting treatment
mia subtypes by flow cytometric analysis of cellular DNA and RNA. Blood 55:282–293, paradigms. Clin Cancer Res 20:5869–5874, 2014.
1980. 73. Garcia-Marco JA, Price CM, Catovsky D: Interphase cytogenetics in chronic lympho-
43. Panayiotidis P, Jones D, Ganeshaguru K, et al: Human bone marrow stromal cells pre- cytic leukemia. Cancer Genet Cytogenet 94:52–58, 1997.
vent apoptosis and support the survival of chronic lymphocytic leukaemia cells in vitro. 74. Malek S: Molecular biomarkers in chronic lymphocytic leukemia. Adv Exp Med Biol
Br J Haematol 92:97–103, 1996. 792:193–214, 2013.
44. Lagneaux L, Delforge A, Bron D, et al: Chronic lymphocytic leukemic B cells but not 75. Bullrich F, Fujii H, Calin G, et al: Characterization of the 13q14 tumor suppressor locus
normal B cells are rescued from apoptosis by contact with normal bone marrow stro- in CLL: Identification of ALT1, an alternative splice variant of the LEU2 gene. Cancer
mal cells. Blood 91:2387–2396, 1998. Res 61:6640–6648, 2001.
45. Ben-Ezra J, Burke JS, Swartz WG, et al: Small lymphocytic lymphoma: A clinicopatho- 76. Calin GA, Dumitru CD, Shimizu M, et al: Frequent deletions and down-regulation of
logic analysis of 268 cases. Blood 73:579–587, 1989. micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc
46. Messmer BT, Messmer D, Allen SL, et al: In vivo measurements document the dynamic Natl Acad Sci U S A 99:15524–15529, 2002.
cellular kinetics of chronic lymphocytic leukemia B cells. J Clin Invest 115:755–764, 77. Mott JL, Kobayashi S, Bronk SF, et al: Mir-29 regulates Mcl-1 protein expression and
2005. apoptosis. Oncogene 26:6133–6140, 2007.
47. Riches JC, Gribben JG: Immunomodulation and immune reconstitution in chronic 78. Pekarsky Y, Santanam U, Cimmino A, et al: Tcl1 expression in chronic lymphocytic
lymphocytic leukemia. Semin Hematol 51:228–234, 2014. leukemia is regulated by miR-29 and miR-181. Cancer Res 66:11590–11593, 2006.
48. D’Arena G, D’Auria F, Simeon V, et al: A shorter time to the first treatment may be pre- 79. Mraz M, Chen L, Rassenti LZ, et al: MiR-150 influences B-cell receptor signaling in
dicted by the absolute number of regulatory T-cells in patients with Rai stage 0 chronic chronic lymphocytic leukemia by regulating expression of GAB1 and FOXP1. Blood
lymphocytic leukemia. Am J Hematol 87:628–631, 2012. 124:84–95, 2014.
49. Huergo-Zapico L, Acebes-Huerta A, Gonzalez-Rodriguez AP, et al: Expansion of NK 80. Quijano S, Lopez A, Rasillo A, et al: Association between the proliferative rate of neo-
cells and reduction of NKG2D expression in chronic lymphocytic leukemia. Correla- plastic B cells, their maturation stage, and underlying cytogenetic abnormalities in
tion with progressive disease. PLoS One 9:e108326, 2014. B-cell chronic lymphoproliferative disorders: Analysis of a series of 432 patients. Blood
50. Riches JC, Davies JK, McClanahan F, et al: T cells from CLL patients exhibit features of 111:5130–5141, 2008.
T-cell exhaustion but retain capacity for cytokine production. Blood 121:1612–1621, 2013. 81. Hjalmar V, Hast R, Kimby E: Cell surface expression of CD25, CD54, and CD95 on
51. Itala M, Vainio O, Remes K: Functional abnormalities in granulocytes predict sus- B- and T-cells in chronic lymphocytic leukaemia in relation to trisomy 12, atypical
ceptibility to bacterial infections in chronic lymphocytic leukaemia. Eur J Haematol morphology and clinical course. Eur J Haematol 68:127–134, 2002.
57:46–53, 1996. 82. Quijano S, Lopez A, Rasillo A, et al: Impact of trisomy 12, del(13q), del(17p), and
52. Cantwell M, Hua T, Pappas J, et al: Acquired CD40-ligand deficiency in chronic lym- del(11q) on the immunophenotype, DNA ploidy status, and proliferative rate of leu-
phocytic leukemia. Nat Med 3:984–989, 1997. kemic B-cells in chronic lymphocytic leukemia. Cytometry B Clin Cytom 74:139–149,
53. Lagneaux L, Delforge A, Bron D, et al: Heterogenous response of B lymphocytes to 2008.
transforming growth factor-beta in B-cell chronic lymphocytic leukaemia: Correlation 83. Bullrich F, Rasio D, Kitada S, et al: ATM mutations in B-cell chronic lymphocytic
with the expression of TGF-beta receptors. Br J Haematol 97:612–620, 1997. leukemia. Cancer Res 59:24–27, 1999.
54. Romano C, De Fanis U, Sellitto A, et al: Effects of preactivated autologous T lympho- 84. Dohner H, Stilgenbauer S, James MR, et al: 11q deletions identify a new subset of B-cell
cytes on CD80, CD86 and CD95 expression by chronic lymphocytic leukemia B cells. chronic lymphocytic leukemia characterized by extensive nodal involvement and infe-
Leuk Lymphoma 44:1963–1971, 2003. rior prognosis. Blood 89:2516–2522, 1997.
55. Jitschin R, Braun M, Buttner M, et al: CLL-cells induce IDOhi CD14+HLA-DRlo 85. Starostik P, Manshouri T, O’Brien S, et al: Deficiency of the ATM protein expression
myeloid-derived suppressor cells that inhibit T-cell responses and promote TRegs. defines an aggressive subgroup of B-cell chronic lymphocytic leukemia. Cancer Res
Blood 124:750–760, 2014. 58:4552–4557, 1998.
56. Hermouet S, Sutton CA, Rose TM, et al: Qualitative and quantitative analysis of human 86. Grever MR, Lucas DM, Dewald GW, et al: Comprehensive assessment of genetic and
herpesviruses in chronic and acute B cell lymphocytic leukemia and in multiple mye- molecular features predicting outcome in patients with chronic lymphocytic leukemia:
loma. Leukemia 17:185–195, 2003. Results from the US Intergroup Phase III Trial E2997. J Clin Oncol 25:799–804, 2007.

Kaushansky_chapter 92_p1527-1552.indd 1544 9/18/15 10:49 AM